Cutting Through the Fog – The Proposed Legislation on FDA and CBD

By: NIHC Staff

This week, National Industrial Hemp Council staff was on Capitol Hill talking to House Agriculture Appropriations staff to gain clarity regarding the House and Senate versions of language directing FDA to move forward with a regulatory structure for hemp-derived CBD products. 

The House version of the annual appropriations bill for USDA and FDA includes an amendment by Congressman Jerry McNerney (D-CA) which provides $100,000 to FDA for a health hazard evaluation to determine safe CBD levels for consumers. The Senate bill includes a provision by Senate Majority Leader Mitch McConnell (R-KY) which provides $2,000,000 for a broader set of activities for the agency to conduct in crafting the regulatory structure for CBD. Some in the industry were confused because Senator McConnell’s provision is report language which sometimes does not have the full effect of a legal requirement. However, staff clarified that the $2,000,000 is a solid and binding level of funding. 

NIHC is supportive of these provisions and appreciates the work of all involved. We will continue to work every angle to achieve a reasonable regulatory structure which protects consumers and the reputation of the industry. NIHC was glad to have the top policy official from FDA as a keynote speaker at our 2019 Hemp Business Summit last month and will continue to lead industry efforts. 

1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *